Digestive diseases (Basel, Switzerland)最新文献

{"title":"Self-management strategies for symptom burden in primary biliary cholangitis are associated with improved health-related quality of life.","authors":"Renate Wisse, Kristina Sokolovic, Johannes Wiegand, Eva Katharina Messer, Andreas Kremer, Carsten Schwenke, Achim Kautz, Diane Langenbacher","doi":"10.1159/ddi/acnag014","DOIUrl":"https://doi.org/10.1159/ddi/acnag014","url":null,"abstract":"<p><p>Introduction PBC patients can experience severe morbidity and extrahepatic symptoms leading to impaired HRQoL; it is proposed that this is due to symptom burdens rather than disease morbidity. There are few medical interventions for PBC symptoms. Many patients rely on self-management strategies to improve symptom burden. However, there is limited research exploring the prevalence and impact of PBC symptom burden on HRQoL. Study aims: 1. analyse the influence of extrahepatic symptoms on HRQoL; 2. measure the effect of self-management strategies on symptom burden and HRQoL. Methods PBC patients in Germany completed a survey on self-management and impact on HRQoL for the symptoms fatigue, pruritus, arthralgia, and sicca syndrome. In addition, the 12-Item short-form health survey and the 10-item PBC quality of life survey were used. Data were collected from January 2021 to January 2022. All data were patient self-reported; no clinical validation data was collected. Descriptive data analysis aimed to identify significant differences in influence on HRQoL, and clusters of self-management strategies. Results Of the 1032 surveys, all four symptom burdens were found to have a statistically significant influence on HRQoL. Data didn't allow evaluation of symptom burden and its link to biochemical disease activity, disease stage and UDCA dosages. Three clusters of reported symptom improvement were identified. A large variety of strategies were reported to improve a respective symptom. Conclusion The study showed significant positive associations between use of self-management strategies and improved HRQoL. Clinicians should support patients in finding the best self-management strategy for their personal disease experience.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149229774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence Trends and Projections of Major Gastrointestinal Cancers in the United States: A SEER-Based Analysis from 2000 to 2022.","authors":"Said Yaseen, Hamza Khoursheed, Ahmed S A Osman, Shaimaa Abdelaziz Abdelmoneim, Basant Atef Ahmed, Mohammad Hamad, Allaa Adnan Ghazi Khirfan, Mohammed Alani Md, Omar Saab Md, Erin Spengler","doi":"10.1159/ddi/acnag010","DOIUrl":"https://doi.org/10.1159/ddi/acnag010","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal (GI) cancers account for a substantial cancer burden, yet contemporary incidence trends and future projections across cancer sites and demographic subgroups remain incompletely characterized. We aimed to analyze incidence trends from 2000-2022 and forecast rates through 2032 for eight major GI cancers in the United States.</p><p><strong>Methods: </strong>Using SEER Research Data (17 registries, 2000-2022), we identified patients with esophageal, gastric, liver, gallbladder, pancreatic, small intestine, and colorectal cancer. Age-adjusted incidence rates were calculated and stratified by sex, age group (<60 vs. ≥60 years), and race (White, Black, Asian/Pacific Islander, American Indian/Alaska Native). Time-series forecasting models (linear regression, ARIMA, ETS, NNAR) were applied to project incidence through 2032.</p><p><strong>Results: </strong>Incidence trends varied markedly by cancer site. Pancreatic cancer showed sustained increases across most subgroups, with projected rates rising from 4.41 to 5.11 per 100,000 by 2032. Colorectal cancer demonstrated divergent age-specific patterns: incidence among individuals ≥60 years is projected to decline (25.48 to 14.89 per 100,000), while early-onset disease (<60 years) is expected to increase (5.35 to 5.84 per 100,000). Liver cancer incidence is forecast to decline (2.18 to 1.42 per 100,000). Esophageal and gastric cancers showed modest increases, while gallbladder cancer remained stable. Substantial disparities persisted by sex (male predominance for most sites, female predominance for gallbladder) and race (highest burden among Asian/Pacific Islander populations).</p><p><strong>Conclusions: </strong>GI cancer incidence trajectories are highly heterogeneous. The projected rise in pancreatic and early-onset colorectal cancers signals urgent needs for targeted prevention, risk-factor modification, and improved early detection strategies in at-risk populations.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maintenance of Efficacy Outcomes at Week 52 among Etrasimod Induction Responders: An Analysis from the Phase 3 ELEVATE UC 52 Trial.","authors":"Bruce Sands, Marla Dubinsky, Brian G Feagan, Remo Panaccione, Vipul Jairath, Andres J Yarur, Michael V Chiorean, Alissa Walsh, Martina Goetsch, Burak Sahin, Christina Cognata, Arcangelo M Abbatemarco, Gulraj S Matharu, Maria Kudela, Subrata Ghosh","doi":"10.1159/ddi/acnag011","DOIUrl":"https://doi.org/10.1159/ddi/acnag011","url":null,"abstract":"<p><strong>Introduction: </strong>Most trials studying advanced therapies for ulcerative colitis (UC) adopted a responder re‑randomization design. By contrast, a treat-through design was utilized in the ELEVATE UC 52 trial to assess etrasimod, an oral, once-daily, selective sphingosine 1 phosphate (S1P) receptor modulator. It is therefore important to contextualize the efficacy of etrasimod given this different study design. We evaluated the efficacy of etrasimod versus placebo at week 52 among induction clinical responders.</p><p><strong>Methods: </strong>In this post hoc analysis of ELEVATE UC 52, selected efficacy endpoints were evaluated at week 52 among all week 12 clinical responders (induction responders), defined as a ≥ 2‑point and ≥ 30% decrease from baseline in modified Mayo score, with a ≥ 1‑point decrease from baseline in rectal bleeding subscore (or an absolute value ≤ 1).</p><p><strong>Results: </strong>In total, 182 patients receiving etrasimod and 52 patients receiving placebo were induction responders. Of these patients, a greater proportion who received etrasimod versus placebo met the criteria for clinical remission (48.9% vs 19.2%; p < 0.001) and all other endpoints assessed at week 52 (p < 0.05). Greater proportions of induction responders compared with the total trial population treated with etrasimod met criteria for clinical remission (48.9% vs 32.5%), endoscopic improvement (56.6% vs 39.1%), and all other endpoints.</p><p><strong>Conclusion: </strong>Greater efficacy was observed among etrasimod induction responders for all assessed endpoints at week 52 when compared with the total ELEVATE UC 52 population, contextualizing the efficacy of etrasimod given the treat-through design of the study.</p><p><strong>Clinicaltrials: </strong>gov identifier: NCT03945188.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IS PYLERA® STILL EFFECTIVE AND SAFE IN PATIENTS INFECTED BY HELICOBACTER PYLORI? A SIX-YEARS, MULTICENTRE, REAL LIFE STUDY.","authors":"Francesco Di Mario, Marilisa Franceschi, Walter Elisei, Pellegrino Crafa, Marcello Picchio, Antonio Tursi","doi":"10.1159/ddi/acnag012","DOIUrl":"https://doi.org/10.1159/ddi/acnag012","url":null,"abstract":"<p><strong>Introduction: </strong>More than ten years after its introduction into clinical practice, we aimed to assess the current real-life effectiveness and safety of bismuth-containing quadruple therapy in patients infected with H. pylori.</p><p><strong>Methods: </strong>Consecutive dyspeptic H. pylori-positive patients were enrolled, both naïve for treatment and already unsuccessfully treated. Patients received Pylera® 3 capsules four times daily plus omeprazole 20 mg or esomeprazole 40 mg bid for 10 days. Eradication was confirmed using a urea-breath test (at least 30 days after the end of treatment). We assessed effectiveness and safety in these patients.</p><p><strong>Results: </strong>One thousand and eighteen consecutive patients were included in the study, 648 (63.7%) treated as first-line and 370 (36.3%) treated after failure of at least one previous eradication course. The vast majority of patients were fully compliant, except 18 (1.8%) subjects, who discontinued treatment due to severe adverse events. H. pylori eradication was achieved in 959/1,000 (95.9%, CI 94.7-97.1%) patients, higher in naïve than in previously treated patients (97.3%, CI 96.1-98.6%, vs 93.3%, CI 90.8-95.9%; p=0.002). Overall, the eradication rate remains significantly high during the observational period. In particular, it was 100% in 2020, 97.8% (CI 95.7-99.9%) in 2021, 100% in 2022, 98.8% (CI 97.3-100%) in 2023, 89.1% (CI 84.6-93.6%) in 2024, and 97.8% (CI 95.5-100%) in 2025: the failures, although minimal, were more present in 2024 (P<0.001). Finally, the eradication rate remained constant from 2020 to 2025.</p><p><strong>Conclusions: </strong>Pylera® remains an effective and safe therapeutic option for curing H. pylori infection in both naïve and previously treated patients.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/ddi/acnag009","DOIUrl":"https://doi.org/10.1159/ddi/acnag009","url":null,"abstract":"<p><p>This is a correction to: Max Ole Hubert, Mahmood Ahmad, Alexander Crispin, Georg Beyer, Julia Mayerle, Simon Sirtl; Obesity Correlates with Severity and Mortality in Acute Pancreatitis: An Updated Meta-Analysis [Dig Dis. 2026; https://doi.org/10.1159/000552102].Upon original publication, the title of this article was incorrectly given as \"Meta-Analysis Obesity Correlates with Severity and Mortality in Acute Pancreatitis: An Updated Meta-Analysis\", instead of \"Obesity Correlates with Severity and Mortality in Acute Pancreatitis: An Updated Meta-Analysis\".This error has now been corrected in the article.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive analysis of colorectal cancer burden in G20 countries from 1990 to 2023 and projections to 2030: findings from the Global Burden of Disease Study 2023.","authors":"Ke Zhang, Zhifei Chen","doi":"10.1159/ddi/acnag008","DOIUrl":"https://doi.org/10.1159/ddi/acnag008","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to comprehensively assess the CRC burden in G20 countries from 1990 to 2023, analyze temporal trends by age and sex, quantify attributable risk factors, and project future burden to 2030.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease Study 2023, we extracted incidence, mortality, and disability-adjusted life years (DALYs). Temporal trends were assessed using estimated annual percentage change (EAPC), factor attribution and Bayesian age-period-cohort (BAPC) models.</p><p><strong>Results: </strong>From 1990 to 2023, incident CRC cases in G20 countries of age-standardized incidence rate (ASIR) showed a modest decline from 27.15 to 26.49 per 100,000 (EAPC: -0.27, 95% CI: -0.34 to -0.21). Peak burden shifted toward older age groups over three decades. Geographic heterogeneity was pronounced: rapidly industrializing countries showed dramatic increases, particularly South Korea (EAPC: 1.71) and Saudi Arabia (EAPC: 3.33). Risk factor attribution revealed dietary risks accounted for 40.0% of deaths and 39.0% of DALYs, followed by high fasting plasma glucose (8.0%), high body mass index (7.0%), low physical activity (7.0%), tobacco use (5.0%), and alcohol consumption (5.0%). BAPC projections indicated continued increases in ASIR from 31.86 per 100,000 in 2024 to 35.10 per 100,000 in 2030, with corresponding rises in mortality and DALY rates.</p><p><strong>Conclusions: </strong>Despite substantial declines in age-standardized mortality and DALY rates, absolute CRC burden in G20 countries has increased dramatically over three decades, driven by population growth and aging. Projected increases to 2030 necessitate strengthened primary prevention, expanded screening coverage.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex- and Smoking-Specific Association between Physical Activity and Digestive Cancer Risk.","authors":"Su Youn Nam, Junwoo Jo, Sung Kook Kim","doi":"10.1159/ddi/acnag006","DOIUrl":"https://doi.org/10.1159/ddi/acnag006","url":null,"abstract":"<p><strong>Background: </strong>This study examined whether suboptimal and excess levels of physical activity (PA) relate to the development of digestive tract cancers, and whether these relationships differ according to sex and smoking history.</p><p><strong>Subjects/methods: </strong>We performed a population-based cohort analysis using records from a nationwide health examination and gastric cancer screening conducted in 2010 and followed up to 2017. Weekly frequency of moderate-intensity PA was stratified into four groups: inactive (0 days/week), light (1-2 days/week), active (3-5 days/week), and highly active (6-7 days/week). The relationship between PA frequency and digestive cancer was quantified via Cox proportional hazards regression, with results expressed as adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>A total of 4.5 million adults were analyzed, of whom 271,247 received a new cancer diagnosis. Relative to light PA group, sedentary behavior was associated with higher risk of overall (aHR 1.02; 95% CI 1.01-1.03), gastric (aHR 1.04; 95% CI 1.01-1.07), liver (aHR 1.10; 95% CI 1.06-1.15), gallbladder (aHR 1.13; 95% CI 1.03-1.24), and colorectal cancers (aHR 1.05; 95% CI 1.02-1.08). Similarly, the highest-frequency PA group showed elevated risks for overall (aHR 1.06; 95% CI 1.04-1.08), gastric (aHR 1.09; 95% CI 1.04-1.14), and colorectal cancers (aHR 1.05; 95% CI 1.00-1.11). Sex and smoking modified these effects: among men, both sedentary behavior and high-frequency PA were associated with greater risks of overall and gastric cancers, whereas sedentary behavior was linked to colorectal cancer risk in men and gallbladder cancer risk in women. In never-smokers, both extremes of PA frequency were associated with elevated risks of gallbladder and gastric cancers.</p><p><strong>Conclusion: </strong>A non-linear, U-shaped pattern of association was observed between PA frequency and digestive cancer risk. These associations were most pronounced in men and in individuals who had never smoked. However, most observed effect sizes were modest, and the findings should be interpreted cautiously given the potential for residual confounding and exposure misclassification.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 30-Year Trends of Gastric Cancer Attributable to Smoking in China and Japan: Demographic Decomposition and Age-Period-Cohort Analysis.","authors":"Xiaoxiao Jia, Xinlong Wang, Xiaoxuan Han, Mengyuan Li, Chong Sheng, Nan Ma, Xiangxu Li, Kaijuan Wang","doi":"10.1159/ddi/acnag005","DOIUrl":"10.1159/ddi/acnag005","url":null,"abstract":"<p><strong>Introduction: </strong>China and Japan have similar cultural backgrounds and lifestyles. This study aimed to assist China or Japan policymakers in allocating healthcare resources by examining secular trends in gastric cancer (GC) mortality attributable to smoking in China and Japan from 1992 to 2021.</p><p><strong>Methods: </strong>Based on the Global Burden of Disease Study 2021, the mortality data for GC attributable to smoking were obtained to assess trends by the annual average percentage change and estimate age, period, and cohort effects by an age-period-cohort model. Smoking-attributable GC deaths were decomposed by decomposition analyses.</p><p><strong>Results: </strong>From 1992 to 2021, age-standardized mortality rates of smoking-attributable GC decreased in China (48.00%) and Japan (73.48%). In China, smoking-attributable GC deaths for both sexes increased by over 26%, mainly driven by population growth, while it decreased in Japan. The main reason for this decline was the mortality rate (-120.10% in males and -106.41% in females). Notably, males had much more smoking-attributable GC deaths compared to females. In the two countries, age and cohort effects were similar, with higher risk of smoking-attributable GC mortality rates observed among the elderly and earlier birth cohorts. However, the period effect decreased rapidly in Japan but increased nearly 1.4 times in China for both sexes during 1992-2001. Divergent trends in smoking-attributable GC mortality between China and Japan may be mainly explained by period effects.</p><p><strong>Conclusion: </strong>From 1992 to 2021, China showed higher risk than Japan in smoking-attributable GC mortality. Therefore, China should learn from Japan's strategies for GC screening and implement more effective tobacco control policies, particularly among earlier birth cohorts and males.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-18/IL-18R1 Involved in Pancreatic Fibrosis via Activating Pancreatic Stellate Cells.","authors":"Ughur Aghamaliyev, Zhiqiang Li, Simon Sirtl, Stefan Munker, Maximilian Weniger, Xiao Yu, Arthur Lewis, Philip Z Brohawn, Banu Astanova, Keith Tan, Güralp O Ceyhan, Merve Bozkurt, Helmut Friess, Jens Werner, Alexandr Bazhin, Jan G D'Haese, Matthias Ilmer, Bernhard W Renz","doi":"10.1159/ddi/acnag004","DOIUrl":"10.1159/ddi/acnag004","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic pancreatitis (CP) is a fibro-inflammatory syndrome characterized by irreversible tissue damage leading to exocrine and endocrine insufficiency, persistent pain, and an increased risk of pancreatic cancer. This study investigates the role of IL-18 in the activation process of pancreatic stellate cells (PSCs) and the progression of pancreatic fibrosis in CP.</p><p><strong>Methods: </strong>A total of 69 CP and 32 normal pancreatic tissue samples were analyzed using qRT-PCR and IHC to assess IL-18R1 expression. Primary PSCs were isolated from murine pancreata and cultured. Effects of recombinant IL-18 on PSC activation were evaluated using qRT-PCR and flow cytometry. Additionally, the impact of IL-18 binding protein (IL-18BP) and IL-18R1 antibody on PSC activation was examined.</p><p><strong>Results: </strong>IL-18R1 expression was significantly upregulated in CP tissues compared to normal pancreatic tissues, correlating with fibrosis severity. Cultured PSCs showed increased α-SMA and IL-18R1 expression over time, indicating activation. Treatment with recombinant IL-18 induced a dose-dependent increase in α-SMA expression, confirming PSC activation. Furthermore, cultured PSCs secreted IL-18, suggesting an autocrine activation mechanism. IL-18BP and IL-18R1 antibody treatments reduced PSC activation, underscoring IL-18's regulatory role.</p><p><strong>Conclusion: </strong>Upregulation of IL-18R1 and its correlation with fibrosis severity in CP highlights the significant role of IL-18 in PSC activation and pancreatic fibrosis. These findings suggest that targeting the IL-18/IL-18R1 axis could be a promising therapeutic strategy to mitigate pancreatic fibrosis in CP, offering potential new avenues for treatment.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-Treatment Histopathological Features Are Associated with Ustekinumab Efficacy in Ulcerative Colitis: A Retrospective Pilot Study.","authors":"Toshiki Horii, Hisatomo Ikehara, Yohei Harada, Naomi Fukagawa, Jun Kanazawa, Tomohiro Betto, Kaoru Yokoyama, Chika Kusano","doi":"10.1159/ddi/acnag003","DOIUrl":"10.1159/ddi/acnag003","url":null,"abstract":"<p><strong>Introduction: </strong>Biologic therapy options for ulcerative colitis (UC) have increased in recent years. Although predicting treatment response may support personalized treatment strategies, the predictive value of histopathological features in UC remains unclear. This exploratory study aimed to evaluate the association between ustekinumab effectiveness and pre-treatment histopathological findings.</p><p><strong>Methods: </strong>This single-center, retrospective, observational pilot study included patients with moderate-to-severe UC who were administered ustekinumab at the Kitasato University Hospital between April 2020 and March 2024. The endpoints were the relationship between pre-treatment histopathological findings, assessed using the Geboes score, and clinical efficacy at weeks 8 and 52, stratified by prior exposure to advanced therapies.</p><p><strong>Results: </strong>The study enrolled 33 patients. Among advanced therapy-naïve (AT-naïve) patients, responders at week 8 were significantly more likely to have low neutrophilic infiltration in the lamina propria than non-responders (66.7% vs. 0%, p = 0.03). Among advanced therapy-exposed (AT-exposed) patients, the degree of neutrophilic or eosinophilic infiltration in colonic tissue at week 8 did not differ significantly between responders and non-responders. Among AT-naïve patients, those who achieved clinical remission at week 52 tended to have mild eosinophilic infiltration in the lamina propria compared with non-responders (80.0% vs. 33.3%, p = 0.07). Among AT-exposed patients, the degree of neutrophilic or eosinophilic infiltration in colonic tissue at week 52 did not differ significantly between responders and non-responders.</p><p><strong>Conclusion: </strong>In moderate-to-severe UC, pre-treatment mucosal histopathological assessment may serve as a treatment response marker. This information can guide development of personalized treatment strategies.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}